Using CRISPR gene editing, a team from Children’s Hospital of Philadelphia (CHOP) and Penn Medicine have thwarted a lethal lung disease in an animal model in which a harmful mutation causes death within hours after birth.
This proof-of-concept study, published today in Science Translational Medicine, showed that in uteroediting could be a promising new approach for treating lung diseases before birth.
“The developing fetus has many innate properties that make it an attractive recipient for therapeutic gene editing,” said study co-leader William H. Peranteau, MD, an investigator at CHOP’s Center for Fetal Research, and a pediatric and fetal surgeon in CHOP’s Center for Fetal Diagnosis and Treatment. “Furthermore, the ability to cure or mitigate a disease via gene editing in mid- to late gestation before birth and the onset of irreversible pathology is very exciting. This is particularly true for diseases that affect the lungs, whose function becomes dramatically more important at the time of birth.”
The lung conditions the team is hoping to solve — congenital diseases such as surfactant protein deficiency, cystic fibrosis, and alpha-1 antitrypsin — are characterized by respiratory failure at birth or chronic lung disease with few options for therapies. About 22 percent of all pediatric hospital admissions are because of respiratory disorders, and congenital causes of respiratory diseases are often lethal, despite advances in care and a deeper understanding of their molecular causes. Because the lung is a barrier organ in direct contact with the outside environment, targeted delivery to correct defective genes is an attractive therapy.
“We wanted to know if this could work at all,” said study co-leader Edward E. Morrisey, PhD, a professor of Cardiovascular Medicine in the Perelman School of Medicine at the University of Pennsylvania. “The trick was how to direct the gene-editing machinery to target cells that line the airways of the lungs.”
The researchers showed that precisely timed in utero delivery of CRISPR gene-editing reagents to the amniotic fluid during fetal development resulted in targeted changes in the lungs of mice. They introduced the gene editors into developing mice four days before birth, which is analogous to the third trimester in humans.
The cells that showed the highest percentage of editing were alveolar epithelial cells and airway secretory cells lining lung airways. In 2018, a team led by Morrisey identified the alveolar epithelial progenitor (AEP) lineage, which is embedded in a larger population of cells called alveolar type 2 cells. These cells generate pulmonary surfactant, which reduces surface tension in the lungs and keeps them from collapsing with every breath. AEPs are a stable cell type in the lung and turn over very slowly, but replicate rapidly after injury to regenerate the lining of the alveoli and restore gas exchange.
In a second experiment, the researchers used prenatal gene editing to reduce the severity of an interstitial lung disease, surfactant protein C (SFTPC) deficiency, in a mouse model that has a common disease-causing mutation found in the human SFTPC gene. One hundred percent of untreated mice with this mutation die from respiratory failure within hours of birth. In contrast, prenatal gene editing to inactivate the mutant Sftpc gene resulted in improved lung morphology and survival of over 22 percent of the animals.
Future studies will be directed toward increasing the efficiency of the gene editing in the epithelial lining of lungs as well as evaluating different mechanisms to deliver gene editing technology to lungs. “Different gene editing techniques are also being explored that may one day be able to correct the exact mutations observed in genetic lung diseases in infants,” Morrisey said.
The Latest on: Gene editing
[google_news title=”” keyword=”gene editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene editing
- In ‘clever’ experiment, scientists use gene editing to treat heart disease in miceon January 13, 2023 at 3:22 pm
Researchers are already using gene editing to tackle rare inherited diseases. But in a new paper, researchers use that tool in mice to treat the leading cause of death in the world: heart disease. In ...
- Heart disease: CRISPR gene editing may repair damaged tissue after a heart attackon January 13, 2023 at 7:33 am
Researchers say a new CRISPR gene editing therapy may help treat heart disease. The scientists also found evidence the therapy can help repair damaged tissue immediately after a heart attack.
- Gene Drives Could Fight Malaria and Other Global Killers but Might Have Unintended Consequenceson January 13, 2023 at 6:08 am
Genetic engineering can fix this by permanently altering insect genes through what is known as a gene drive. This technology allows a chosen set of genes to alter an animal’s biology in some way, such ...
- This CRISPR Researcher Says Gene Editing Isn't Playing Godon January 12, 2023 at 4:03 pm
CRISPR — the gene editing technology developed by researchers Jennifer Doudna and Emmanuelle Charpentier, who won the Nobel Prize for their achievement — is a remarkable, almost otherworldly ...
- 5 questions facing gene therapy in 2023on January 12, 2023 at 2:36 pm
Buoyed by recent approvals, the field faces a pivotal year that’s likely to bring new treatments as well as more challenges.
- CRISPR for high cholesterol: 10 Breakthrough Technologies 2023on January 12, 2023 at 8:09 am
New forms of the gene-editing tool could enable treatments for common diseases. Verve Therapeutics, Beam Therapeutics, Prime Medicine, Broad Institute 10 to 15 years Last year, a New Zealand woman ...
- Washington State University study reveals its more about taste than gene editing for table grapeson January 10, 2023 at 7:16 pm
Despite some hesitation about gene-edited foods, taste trumps everything, according to a Washington State University-led survey of U.S. consumers.For the study published in the journal PLOS One, ...
- Researchers realize rapid customization of tomato cultivars with different fruit colors via multiplex gene editingon January 10, 2023 at 4:00 pm
The color of fruits and vegetables is an important horticultural trait, which greatly affects consumer preferences. In tomato, one of the most consumed vegetables worldwide, fruit color is determined ...
- Asklepios partners with ReCode on gene-editing platformon January 10, 2023 at 5:57 am
Asklepios has entered into a research partnership and option agreement with ReCode for exploring its single-vector gene-editing platform.
- Gene Editing Market : New Business Strategies And Forecast By 2028 with Top Countries Dataon January 10, 2023 at 12:39 am
Final Report will add the analysis of the impact of Russia-Ukraine War and COVID-19 on this Gene Editing industry.
via Bing News